Cullen Capital Management, LLC sold 6,565,339 shares of Kenvue for about $149.46 million, representing 1.7% of 13F assets under management in Q2 2025. Post-trade, Cullen holds 2,484,940 shares valued at $52.01 million, with Kenvue comprising 0.6% of AUM as of Q2 2025.

The fund reduced its Kenvue stake to 0.6% of AUM after selling 6.6 million shares, with top holdings including JPM, CSCO, BAC, NVS, and DUK. Kenvue’s stock price was $16.34 as of 9/29/25, down 29.4% in the past year.

Kenvue Inc. is a global consumer health company with brands like Tylenol and Listerine. Despite KVUE stock’s underperformance, it generates $1.4 billion in profit, offers a 5.07% dividend yield, and operates in self-care, skin health, and essential health segments.

Cullen’s reduction in Kenvue stake raises questions about the company’s future growth and margins. Investors should monitor earnings and dividend sustainability, as further institutional actions may follow Cullen’s lead. The consumer health sector’s defensiveness may face challenges amidst market headwinds.

Read more at Nasdaq: Cullen Trims KVUE Stake With $149.5M Share Sale